NICE Appraisal Programmes for MedTech

Manufacturers of medical devices and diagnostics (Medtech) seeking access to the UK National Health Service (NHS) in England increasingly need to consider value for money. This is because NHS decision-makers weigh the clinical benefits of new technologies against the (acquisition and other) costs associated with their adoption and use.  There are a number of different organisations making decisions about the utilisation of healthcare resources. In the NHS, funding decisions are largely taken at a local level by Clinical Commissioning Groups (CCGs), NHS Trusts and other provider organisations, with NHS England making specialist-commissioning decisions nationally for England and Wales.

This paper sets out to provide some clarity for device and diagnostic manufacturers on the NICE appraisal programmes which relate specifically to them and the important features to take into account when navigating these processes.

Asset 7
  • Washington, D.C.
  • Berlin
  • Brussels
  • London
  • Los Angeles
  • Minneapolis
  • New England
  • New York